| 000 | 01647 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250518012609.0 | ||
| 264 | 0 | _c20190325 | |
| 008 | 201903s 0 0 eng d | ||
| 022 | _a1471-2407 | ||
| 024 | 7 |
_a10.1186/s12885-018-5134-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRacioppi, Marco | |
| 245 | 0 | 0 |
_aElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes. _h[electronic resource] |
| 260 |
_bBMC cancer _cDec 2018 |
||
| 300 |
_a1224 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Intravesical |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibiotics, Antineoplastic _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInfusion Pumps _xtrends |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMitomycin _xadministration & dosage |
| 650 | 0 | 4 | _aMycobacterium bovis |
| 650 | 0 | 4 |
_aNeoplasm Invasiveness _xpathology |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSalvage Therapy _xmethods |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Failure |
| 650 | 0 | 4 |
_aUrinary Bladder Neoplasms _xdiagnosis |
| 700 | 1 | _aDi Gianfrancesco, Luca | |
| 700 | 1 | _aRagonese, Mauro | |
| 700 | 1 | _aPalermo, Giuseppe | |
| 700 | 1 | _aSacco, Emilio | |
| 700 | 1 | _aBassi, Pier Francesco | |
| 773 | 0 |
_tBMC cancer _gvol. 18 _gno. 1 _gp. 1224 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s12885-018-5134-7 _zAvailable from publisher's website |
| 999 |
_c29135830 _d29135830 |
||